logo
Sickle Cell Mission identifies over two lakh patients through mass screening

Sickle Cell Mission identifies over two lakh patients through mass screening

The Hindu17 hours ago

Ganesh V. Dante could not understand why his seven-year-old son was frequently falling ill. A traditional doctor in his village in Chandrapur, Maharashtra, had been treating the child since birth, 'but his condition never really improved.'
'It was only through screening under the National Sickle Cell Anaemia Elimination Mission (NSCAEM), launched in 2023 by Prime Minister Narendra Modi, that my son was found to have sickle cell and has been getting treatment for it. He is doing much better now and has even started school,' Mr. Ganesh said.
His son is among the more than 5.72 crore people who have been screened under NSCAEM so far, leading to the identification of 2.09 lakh persons with the disease and 16.3 lakh trait carriers, according to figures released recently by the Union Health Ministry.
'The goal of the mission now is to screen approximately seven crore people under the age of 40 across 17 States till 2025-26, aiming to enhance the diagnosis, treatment and care for those with sickle cell disease,' said Manisha Madkaikar, Director, Indian Council of Medical Research-Centre for Research, Management and Control of Haemoglobinopathies.
She emphasised that sickle cell disease can be contained to a large extent by ensuring all pregnant women and newborns are screened and followed up for early diagnosis and timely care. 'This is the key to countering the growing numbers of patients with sickle cell,' she added.
The nationwide screening, being carried out under the National Health Mission (NHM), places a particular emphasis on tribal populations and includes States such as Maharashtra, Odisha, Chhattisgarh, Jharkhand, Uttar Pradesh, Bihar, Gujarat, and Rajasthan.
'The National Sickle Cell Elimination Mission has given the guidelines. The first is universal screening — in areas with a very high prevalence of sickle cell disease, the entire population under the age of 40 is screened. Currently, the plan is to screen nearly seven crore individuals for sickle cell disease,' Dr. Madkaikar said.
India carries a significant burden of sickle cell disease (SCD), particularly among tribal populations. More than 50% of cases are concentrated in States such as Madhya Pradesh, Maharashtra, Odisha, Jharkhand, and Chhattisgarh.
'Working with tribal populations is a challenge due to their faith in traditional systems of medicine, deep-rooted fear of the modern system, lack of accessibility, and the need for timely follow-up,' Dr. Madkaikar said. She noted that Maharashtra now ensures hydroxyurea — the key medicine for SCD — reaches patients through trained frontline health workers.
Sickle cell disease is a genetic blood disorder characterised by abnormal haemoglobin, which causes red blood cells to become rigid and sickle-shaped, leading to a host of health complications. While particularly prevalent in tribal communities, the disease also affects non-tribal groups.
Rasmi Palassery, Consultant, Paediatric Oncologist, Haematologist and Bone Marrow Transplant Physician at Ramaiah Institute of Oncology, Bengaluru, pointed to several gaps in India's response to SCD.
'There is a need for a dynamic national registry to determine the actual load of sickle cell anaemia in our country, aggressive screening of pregnant women and newborns, and the provision of comprehensive care,' she said. 'This is vital as sickle cell anaemia is, in the end, a multi-system, chronic disorder.'
'This, coupled with the social stigma, makes families delay seeking help, as they want to hide the fact that this disease exists. India also needs specialised care centres, diagnostic laboratories, and trained staff to ensure early diagnosis and care,' she added.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Early Clues, Lifelong Impact: Understanding Sickle Cell DiseaseUntitled Story
Early Clues, Lifelong Impact: Understanding Sickle Cell DiseaseUntitled Story

Hindustan Times

time23 minutes ago

  • Hindustan Times

Early Clues, Lifelong Impact: Understanding Sickle Cell DiseaseUntitled Story

Sickle Cell Disease (SCD) is one of India's persistent public health concerns. It is a genetic blood disorder that alters the shape and function of red blood cells. These cells become sickle-shaped, stiff, and sticky, causing them to block blood flow. This can result in a range of complications, from pain crisis, extreme fatigue, infections, delayed growth, and organ damage. India faces 1.4 million SCD cases, with 20 million carriers nationwide SCD has a significant prevalence in India, particularly in certain high-risk regions across central and eastern states. According to the Indian Council of Medical Research (ICMR), approximately 20 million individuals carry the sickle cell trait, with over 1.4 million cases of SCD reported nationwide. Early identification remains the most effective way to prevent long-term damage. Why Early Detection Matters Many babies are screened for SCD at birth in countries with strong neonatal screening programs. In India, however, awareness is still growing, and universal screening is being scaled gradually under the National Sickle Cell Anaemia Elimination Mission. Launched by Honourable Prime Minister Narendra Modi in July 2023, this mission aims to screen over 7 crore people by 2026 and eliminate the disease as a public health issue by 2047. Source: PIB – National Sickle Cell Mission, July 2023 Unfortunately, in the absence of early diagnosis, children with SCD may go undiagnosed until they experience a severe health episode. Subtle signs often mistaken for common ailments can be early indicators that something is wrong. Early Signs You Shouldn't Ignore 1. Unexplained Fatigue or Weakness Children with SCD often suffer from anaemia, resulting in chronic fatigue or breathlessness even after mild exertion. 2. Swollen Hands or Feet in Infants A condition known as "dactylitis," or painful swelling in hands and feet, can be one of the earliest signs of blocked blood flow due to sickled cells. 3. Recurring Infections The spleen, which plays a key role in fighting infections, may become damaged early in children with SCD, making them more vulnerable to fevers, pneumonia, and other bacterial infections. 4. Yellowing of the Eyes or Skin Jaundice is common in children with SCD due to the rapid breakdown of defective red blood cells. 5. Delayed Growth and Puberty Lack of healthy red blood cells can impact physical growth and hormonal development. 6. Pain Episodes or 'Pain Crises' Even without visible injury, children may complain of severe pain in the chest, abdomen, bones, or joints. These episodes can last hours or days. 'Sickle Cell Disease is not curable in all cases, but it is preventable and manageable. Early screening—especially premarital or prenatal—can significantly reduce the disease burden. And for those diagnosed, timely medical care can vastly improve quality of life,' says Dr. Dipty Jain, Former Chair, Dept of Pediatrics, Government Medical College, Nagpur, and Chairman of the Task Force on SCD Elimination. Taking Action If your child or someone in your family is showing multiple signs listed above—or if there is a family history of the disease—consult a medical professional. A simple blood test, such as the haemoglobin electrophoresis test or solubility test, can detect whether someone is a carrier or has the disease. Treatment and Management Options While there is currently no universal cure, treatment options can help manage the disease effectively: Hydroxyurea: A medication that reduces pain episodes and the need for transfusions. Vaccinations & Antibiotics: Essential to reduce infection risk, especially in young children. Routine Monitoring: Regular health checkups to monitor organ function and growth. Bone Marrow Transplant: The only known potential cure for some patients, especially children with matched donors. A National Call to Action India's National Sickle Cell Anaemia Elimination Mission is now operational in 17 states and 278 districts. As of March 2024, June 2025, over 5,79,35,688 crore individuals have been screened. The mission prioritizes awareness, outreach, and community engagement, especially in regions with higher genetic prevalence. Source: In Closing Sickle Cell Disease rarely announces itself loudly. It enters quietly, through pain episodes, fatigue, mild fevers, or a child who seems to fall ill too often. But by recognising the early signs, seeking testing, and beginning treatment, we can change the story. Every timely diagnosis is a step towards healthier, longer lives and a future free from the burden of this inherited condition. Sources: National Sickle Cell Anaemia Elimination Mission Guidelines – NHM, MoHFW Press Information Bureau: National Sickle Cell Mission Launch – July 2023 UN Resolution A/RES/63/237 – Recognition of World Sickle Cell Day PIB: Progress Update – March 2024 Note: This article has been produced on behalf of the brand by HT Brand Studio and does not have the journalistic/editorial involvement of Hindustan Times. The information provided does not constitute medical advice. Please consult a registered medical practitioner for health-related concerns.

ICMR in process to procure 2 more mobile BSL-3 laboratories to bolster India's outbreak response
ICMR in process to procure 2 more mobile BSL-3 laboratories to bolster India's outbreak response

Time of India

time3 hours ago

  • Time of India

ICMR in process to procure 2 more mobile BSL-3 laboratories to bolster India's outbreak response

New Delhi: The Indian Council of Medical Research ( ICMR ) has initiated the process of procuring two more Mobile BSL-3 (MBSL-3) laboratories to step up outbreak response capabilities and bolster public health delivery, especially in remote and inaccessible areas. Called RAMBAAN , there are currently two such laboratories - each stationed at ICMR's two institutes, the National Institute of Virology in Pune and the RMRC in Gorakhpur, UP. RAMBAAN is the first of its kind Rapid Action Mobile BSL-3 laboratory and is fully indigenous. It is field-deployable and designed to meet enhanced diagnostic demands during outbreaks of known and unknown high-risk pathogens. An initiative of ICMR, it was developed in partnership with Klenzaids Contamination Controls Private Limited, Mumbai, under the patronage of Pradhan Mantri-Ayushman Bharat Health Infrastructure Mission, Ministry of Health and Family Welfare, the apex research institute said. The MBSL-3 was successfully deployed and operationalised for the first time during the Nipah virus (NiV) outbreak in Kozhikode, Kerala, in September 2023 and again in Malappuram district of the state in July 2024, it said. This "laboratory on wheels" is built on a heavy-duty Bharat Benz vehicle chassis, compliant with BS-VI norms, designed to operate at extreme temperatures and altitudes and bears a maximum load capacity 17,000 kgs. It is classified as a Type-IV Rapid Response Mobile Laboratory (RRML) as per WHO GOARN RRML laboratory network classification. The laboratory is designed to maintain a negative air pressure environment and is equipped with an advanced heating, ventilation, and air conditioning (HVAC) system with HEPA filters. It also features a double-door autoclave and a biological liquid effluent decontamination (BLED) and hydrogen peroxide (H2O2) fogger system for biological waste management. The MBSL-3 laboratory 's work area is divided into four zones -- zone-1 (driver and outer change room), zone-2 (shower and inner change room), zone-3 (main laboratory), and zone-4 (material staging and decontamination area). Key installations within these zones include biological safety cabinets (Class II A2), an intelligent programmable logic controller system, a dynamic pass box, and an entry-exit shower system with biometric control. The laboratory's power supply can be from a direct electric supply or a diesel generator, with an uninterrupted power supply (UPS) and petrol generators for backup. Communication within the laboratory is facilitated by walkie-talkies and real-time surveillance through CCTVs.

ICMR to procure 2 more mobile BSL-3 labs to boost India's outbreak response
ICMR to procure 2 more mobile BSL-3 labs to boost India's outbreak response

Business Standard

time6 hours ago

  • Business Standard

ICMR to procure 2 more mobile BSL-3 labs to boost India's outbreak response

The Indian Council of Medical Research (ICMR) has initiated the process of procuring two more Mobile BSL-3 (MBSL-3) laboratories to step up outbreak response capabilities and bolster public health delivery, especially in remote and inaccessible areas. Called RAMBAAN, there are currently two such laboratories each stationed at ICMR's two institutes, the National Institute of Virology in Pune and the RMRC in Gorakhpur, UP. RAMBAAN is the first of its kind Rapid Action Mobile BSL-3 laboratory and is fully indigenous. It is field-deployable and designed to meet enhanced diagnostic demands during outbreaks of known and unknown high-risk pathogens. An initiative of ICMR, it was developed in partnership with Klenzaids Contamination Controls Private Limited, Mumbai, under the patronage of Pradhan Mantri-Ayushman Bharat Health Infrastructure Mission, Ministry of Health and Family Welfare, the apex research institute said. The MBSL-3 was successfully deployed and operationalised for the first time during the Nipah virus (NiV) outbreak in Kozhikode, Kerala, in September 2023 and again in Malappuram district of the state in July 2024, it said. This "laboratory on wheels" is built on a heavy-duty Bharat Benz vehicle chassis, compliant with BS-VI norms, designed to operate at extreme temperatures and altitudes and bears a maximum load capacity 17,000 kgs. It is classified as a Type-IV Rapid Response Mobile Laboratory (RRML) as per WHO GOARN RRML laboratory network classification. The laboratory is designed to maintain a negative air pressure environment and is equipped with an advanced heating, ventilation, and air conditioning (HVAC) system with HEPA filters. It also features a double-door autoclave and a biological liquid effluent decontamination (BLED) and hydrogen peroxide (H2O2) fogger system for biological waste management. The MBSL-3 laboratory's work area is divided into four zones -- zone-1 (driver and outer change room), zone-2 (shower and inner change room), zone-3 (main laboratory), and zone-4 (material staging and decontamination area). Key installations within these zones include biological safety cabinets (Class II A2), an intelligent programmable logic controller system, a dynamic pass box, and an entry-exit shower system with biometric control. The laboratory's power supply can be from a direct electric supply or a diesel generator, with an uninterrupted power supply (UPS) and petrol generators for backup. Communication within the laboratory is facilitated by walkie-talkies and real-time surveillance through CCTVs.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store